

## Drug Monograph

Drug/Drug **Ilevro™ (nepafenac) ophthalmic suspension /**  
 Class: **ophthalmic NSAID**  
 Prepared for: MO HealthNet  
 Prepared by: Xerox Heritage, LLC

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

<b>Purpose:</b>	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
<b>Dosage Forms:</b>	Each 1 mL of Ilevro suspension contains 3 mg nepafenac. Ilevro suspension comes in a 4 mL dropper bottle containing 1.7 mL of the suspension.
<b>Manufacturer:</b>	ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA © 2012 Novartis
<b>Indications:</b>	Ilevro™ (nepafenac ophthalmic suspension), 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery.
<b>Costs:</b>	\$ 141.61 per 1.7 mL of Ilevro ophthalmic suspension) in a 4mL dropper bottle. Wholesale Acquisition Cost
<b>Summary of Findings:</b>	This drug is currently being considered for inclusion into the state specific Preferred Drug List and is currently under solicitation.
<b>Status Recommendation:</b>	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Clinical Edit <input checked="" type="checkbox"/> PDL
<b>Type of PA Criteria:</b>	<input type="checkbox"/> Increased Risk of ADE <input type="checkbox"/> Preferred Agent <input type="checkbox"/> Appropriate Indications <input checked="" type="checkbox"/> Under Solicitation

Prepared By: Kathleen Wilbers, Pharm.D.  
 Date: February 7, 2013